These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1134 related articles for article (PubMed ID: 14555312)

  • 1. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
    Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM
    Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
    Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
    Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Jones LE
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.